MSC-Derived Cell Selection for Stable Trophic Immunosuppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge of generating therapeutically effective numbers of mesenchymal stem cells (MSCs) is hindered by the loss of multipotency and changes in therapeutic properties during prolonged culture, making it difficult to produce homogeneous populations suitable for robust cell-based medicines.
Innovation Solution
Selecting MSC-derived cells based on low MMP13 gene expression and high TIMP-1 protein secretion, characterized by the marker profile CD90+; CD105+; CD45-; high TIMP-1 secretion and low MMP13 gene expression, to enrich populations that retain trophic and immunosuppressive activities without phenotypic differentiation capacity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If MSCs are cultured for long periods to produce large numbers of cells, then cell quantity increases, but multipotency and therapeutic properties are lost
Solution Approach 1:
The patent applies preliminary action by establishing specific culture condition parameters before therapeutic use to preserve multipotency. The method pre-defines acceptable ranges for passage number, doubling time, and morphological characteristics, ensuring that cells are harvested at optimal points before therapeutic properties deteriorate, thus resolving the contradiction between producing sufficient cell numbers and maintaining reliability.
Solution Approach 2:
The patent employs parameter changes by monitoring and controlling multiple culture parameters simultaneously (passage number, doubling time, morphological features) to maintain therapeutic property retention while allowing cell expansion. By dynamically adjusting these parameters based on observed cell characteristics, the method enables production of large cell numbers without losing multipotency.
2Productivity
If MSCs are cultured extensively to generate therapeutically effective numbers, then productivity increases, but manufacturing precision deteriorates due to population heterogeneity
Solution Approach 1:
The patent applies feedback by continuously monitoring cell population characteristics during culture expansion and using this information to adjust culture conditions. The method tracks morphological changes, doubling times, and other parameters to detect shifts in population homogeneity, enabling real-time corrections that maintain manufacturing precision while sustaining high productivity throughout the culture process.
Solution Approach 2:
The method establishes preliminary criteria for acceptable population homogeneity before therapeutic use, defining specific ranges for passage numbers and morphological characteristics. By pre-setting these quality thresholds, the patent ensures that even during extensive culture for high productivity, the cell population maintains the required homogeneity and manufacturing precision.
3Quantity of substance
If MSCs are passaged multiple times to increase cell yield, then quantity improves, but multipotency deteriorates
Solution Approach 1:
The patent uses parameter changes by identifying and controlling the relationship between passage number and multipotency retention. The method establishes specific passage number thresholds and monitors changes in differentiation capacity at each passage, allowing optimization of the culture duration to achieve maximum cell yield while preserving the required level of multipotency for therapeutic effectiveness.
Solution Approach 2:
The method applies preliminary action by pre-determining acceptable passage number ranges and morphological characteristics that correlate with retained multipotency. By setting these parameters in advance, the patent enables planners to stop cell culture at the optimal point where sufficient cell yield has been achieved but before multipotency deteriorates below therapeutic thresholds.
Data Source
Figure 1A~1D
Figure 2
Figure 3A~3F
AI summary
Provided are populations of cells enriched for MSC-derived cells that are: CD90+; CD105+; CD45-; as well as TIMP-1 secretion high, and MMP13 gene expression low. Such populations of cells are useful as medicaments in contexts where it is desired to make use of the trophic or immunosuppressive therapeutic effects of MSCs, but to avoid activity associated with the capacity of MSCs to undergo phenotypic differentiation. Populations of cells of the invention are useful in the treatment of a condition selected from the group consisting of: osteoarthritis; myocardial infarction; meniscus cartilage injury (such as torn meniscus); ligament injury (such as torn ligament); injuries to the skin; and soft tissue injury. They may also be used in treatment of a disease selected from the group consisting of: haematological disease; graft- versus-host disease; and inflammatory disease.